SCHEMBL7801334

SCHEMBL7801334

CCOc1cc(OCC)c(C(=O)OC)cc1C(C)=O

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 2/20 0.71
▸ CYP3A4 P08684 1/20 0.71
▸ TDP1 Q9NUW8 1/20 0.57
▸ CA9 Q16790 1/20 0.49
▸ ALDH1A1 P00352 1/20 0.48
▸ HTT P42858 1/20 0.48
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ KDM4E B2RXH2 2/20 0.45
▸ KMT2A Q03164 2/20 0.45
▸ CREBBP Q92793 4/20 0.45
▸ LMNA P02545 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ KCNK3 O14649 1/20 0.40
▸ KCNK9 Q9NPC2 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ POLB P06746 2/20 0.40
▸ NPC1 O15118 3/20 0.40
▸ GAA P10253 1/20 0.40
▸ RAB9A P51151 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10268423 0.87 TSHR (0.53) TSHRCYP3A4TDP1CA9ALDH1A1
SCHEMBL10498013 0.83 TSHR (1.00) TSHRCYP3A4TDP1CA9HTT
SCHEMBL19339164 0.83 TDP1 (0.51) TSHRCYP3A4TDP1ALDH1A1HTT
SCHEMBL27400702 0.83 TSHR (0.61) TSHRCYP3A4TDP1ALDH1A1HTT
SCHEMBL7802436 0.82 TSHR (0.76) TSHRCYP3A4TDP1CA9ALDH1A1
SCHEMBL8900845 0.82 GAA (0.54) TSHRCYP3A4CA9ALDH1A1HTT
SCHEMBL7802388 0.81 TDP1 (0.52) TSHRCYP3A4TDP1ALDH1A1HTT
SCHEMBL20391495 0.81 TDP1 (0.49) TSHRCYP3A4TDP1ALDH1A1HTT
SCHEMBL1646646 0.79 KDM4E (0.54) TSHRCYP3A4TDP1ALDH1A1HTT
SCHEMBL7160525 0.79 CREBBP (0.61) TSHRTDP1ALDH1A1HTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010025045-A1 Substituted isoquinoline derivatives and their use as anticonvulsants SMITHKLINE BEECHAM P.L.C. 2001-09-27 — — US disclosed
EP-1025087-A1 SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS SMITHKLINE BEECHAM PLC (GB) 2000-08-09 — — EP disclosed
WO-1999021836-A1 SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS SMITHKLINE BEECHAM PLC (GB) 1999-05-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010025045-A1 Substituted isoquinoline derivatives and their use as anticonvulsants INA, GRIN2C, GRIN2A TSHR 4289/4885CYP3A4 168/4885TDP1 2520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback